Leerink Partners analyst Thomas Smith has reiterated their bullish stance on TRML stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thomas Smith has given his Buy rating due to a combination of factors surrounding Tourmaline Bio’s promising developments with their drug pacibekitug. The recent data from the Phase 2 TRANQUILITY trial presented at the European Society of Cardiology Congress highlighted significant reductions in hs-CRP levels in patients with atherosclerotic cardiovascular disease. These reductions were consistent across various patient subgroups and accompanied by improvements in other key biomarkers, demonstrating the drug’s efficacy and favorable safety profile.
Furthermore, pacibekitug’s less frequent dosing schedule offers a competitive advantage over existing treatments. The company’s plans for a Phase 3 cardiovascular outcomes trial and a proof-of-concept study in a new indication suggest potential for substantial market impact. With these developments, Smith sees Tourmaline Bio as undervalued, especially with upcoming data readouts that could further enhance the company’s valuation. This strategic positioning makes TRML a top pick for the coming year.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $58.00 price target.